NCT07669935Recruiting
Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study
A Multi-Site, Prospective, Two-Part Longitudinal, Observational Cohort Study Of Pregnant Women To Evaluate Biomarkers For Prediction Of Pregnancy Complications
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\] and risk of adverse outcomes.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5500 (estimated)
- First submitted
- 21 Jun 2026
- Start date
- 8 Sept 2026
- Primary completion date
- 1 Jul 2028
- Lead sponsor
- Medicines360
- NCT number
- NCT07669935
What you commit to
- Study type: Observational
- Planned participants: 5500
- From 8 Sept 2026 to the primary completion date, 1 Jul 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Multiple gestation
- Inability to provide blood
- Known fetal chromosomal abnormalities or structural Anomaly (a structural or functional defect with the following three characteristics: 1) of prenatal origin; 2) present at the time of live birth or fetal demise, or in utero; 3) affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual
- Known or anticipated inability to complete study follow-up through delivery at the study site (e.g., planned relocation, transfer of obstetric care to a non-participating institution, or other circumstances making delivery outcome data unavailable)
- Current or recent (within two months) participation in an interventional clinical study.
Who the study is looking for
- Age ≥18 years
- Nulliparous (no previous births ≥20wk GA)
- Single viable fetus at the dating ultrasound scan with an ultrasound estimated gestational age of 10 0/7-17 6/7 weeks of gestation
- Ability to consent and comply with study procedures and follow-up
Age in the registry: 18 years to 99 years · Sex: Female · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Woman's Hospital Coordinator of this site? Confirm its status | Baton Rouge | United States | Recruiting |
| St. Lawrence Health Coordinator of this site? Confirm its status | Potsdam | United States | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.